A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:34
|
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 12期
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
  • [1] Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
    Raji, Annaswamy
    Xu, Zhi Jin
    Lam, Raymond L. H.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Engel, Samuel S.
    [J]. DIABETES THERAPY, 2020, 11 (10) : 2419 - 2428
  • [2] Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
    Annaswamy Raji
    Zhi Jin Xu
    Raymond L. H. Lam
    Edward A. O’Neill
    Keith D. Kaufman
    Samuel S. Engel
    [J]. Diabetes Therapy, 2020, 11 : 2419 - 2428
  • [3] Safety and efficacy of sitagliptin compared with dapagliflozin in patients with type 2 diabetes, mild renal impairment, and inadequate glycaemic control on metformin ± a sulfonylurea
    Raji, A.
    Scott, R.
    Morgan, J.
    Zimmer, Z.
    Lam, R. L. H.
    O'Neill, E. A.
    Kaufman, K. D.
    Engel, S. S.
    [J]. DIABETOLOGIA, 2018, 61 : S379 - S380
  • [4] Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
    Chan, J. C. N.
    Scott, R.
    Ferreira, J. C. Arjona
    Sheng, D.
    Gonzalez, E.
    Davies, M. J.
    Stein, P. P.
    Kaufman, K. D.
    Amatruda, J. M.
    Williams-Herman, D.
    [J]. DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 545 - 555
  • [5] A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone
    Wang, Weiqing
    Ning, Guang
    Ma, Jianhua
    Liu, Xiaomin
    Zheng, Shaoxiong
    Wu, Fan
    Xu, Lei
    O'Neill, Edward A.
    Fujita, Kenji P.
    Engel, Samuel S.
    Kaufman, Keith D.
    Shankar, R. Ravi
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 693 - 699
  • [6] Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus
    Ji, Linong
    Han, Ping
    Wang, Xiaoyue
    Liu, Jingdong
    Zheng, Shaoxiong
    Jou, Ying-Ming
    O'Neill, Edward A.
    Golm, Gregory T.
    Engel, Samuel S.
    Kaufman, Keith D.
    Shankar, R. Ravi
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (05): : 727 - 736
  • [7] Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus
    Tago, Motoko
    Oyama, Jun-ichi
    Sakamoto, Yoshiko
    Shiraki, Aya
    Uchida, Fumi
    Chihara, Atsuko
    Ikeda, Hideo
    Kuroki, Shigetaka
    Gondo, Shigeki
    Iwamoto, Taketo
    Uchida, Yasufumi
    Node, Koichi
    [J]. GERIATRICS & GERONTOLOGY INTERNATIONAL, 2018, 18 (04) : 631 - 639
  • [8] Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study
    Frias, Juan P.
    Zimmer, Zachary
    Lam, Raymond L. H.
    Amorin, Guillermo
    Ntabadde, Catherine
    Iredale, Carol
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    Makimura, Hideo
    Crutchlow, Michael F.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1128 - 1135
  • [9] Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
    Iwamoto, Y.
    Tajima, N.
    Kadowaki, T.
    Nonaka, K.
    Taniguchi, T.
    Nishii, M.
    Ferreira, J. C. Arjona
    Amatruda, J. M.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (07): : 613 - 622
  • [10] Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
    Aschner, P.
    Katzeff, H. L.
    Guo, H.
    Sunga, S.
    Williams-Herman, D.
    Kaufman, K. D.
    Goldstein, B. J.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (03): : 252 - 261